| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.809 | 0.004 | 0.809 | Psychostimulant | 0.708 0.004 DBMET02308 | ||
| 0.666 | 0.002 | 0.666 | Dopamine transporter inhibitor | 0.513 0.002 DBMET02308 | ||
| 0.616 | 0.004 | 0.616 | 5 Hydroxytryptamine uptake inhibitor | 0.478 0.004 DBMET02308 | ||
| 0.572 | 0.003 | 0.572 | Dopamine uptake inhibitor | 0.222 0.005 DBMET02308 | ||
| 0.539 | 0.003 | 0.539 | Adrenaline uptake inhibitor | 0.452 0.004 DBMET02308 | ||
| 0.507 | 0.025 | 0.507 | Calcium channel L-type activator | 0.475 0.038 DBMET02308 | ||
| 0.505 | 0.027 | 0.505 | Vasodilator, peripheral | 0.387 0.059 DBMET02308 | ||
| 0.469 | 0.013 | 0.469 | Sigma receptor agonist | 0.437 0.017 DBMET02308 | ||
| 0.447 | 0.031 | 0.447 | Spasmolytic | 0.358 0.05 DBMET02308 | ||
| 0.395 | 0.026 | 0.395 | Calcium channel activator | 0.356 0.046 DBMET02308 | ||
| 0.343 | 0.018 | 0.472 | Tyrosine 3 hydroxylase inhibitor | 0.472 0.004 DBMET02308 | DBMET02308 | |
| 0.356 | 0.032 | 0.37 | Insulysin inhibitor | 0.37 0.028 DBMET02308 | DBMET02308 | |
| 0.363 | 0.049 | 0.363 | Vasodilator, coronary | 0.359 0.051 DBMET02308 | ||
| 0.376 | 0.074 | 0.502 | Immunosuppressant | 0.502 0.032 DBMET02308 | DBMET02308 | |
| 0.356 | 0.055 | 0.433 | 5 Hydroxytryptamine release stimulant | 0.433 0.039 DBMET02308 | DBMET02308 | |
| 0.302 | 0.012 | 0.302 | Anesthetic local | 0.192 0.034 DBMET02308 | ||
| 0.259 | 0.009 | 0.259 | Acetylcholine nicotinic antagonist | 0.164 0.017 DBMET02308 | ||
| 0.294 | 0.048 | 0.348 | 5 Hydroxytryptamine uptake stimulant | 0.348 0.026 DBMET02308 | DBMET02308 | |
| 0.281 | 0.044 | 0.281 | 5 Hydroxytryptamine 1E antagonist | 0.241 0.085 DBMET02308 | ||
| 0.256 | 0.02 | 0.256 | Cholinergic antagonist | 0.197 0.033 DBMET02308 | ||
| 0.272 | 0.041 | 0.272 | Anesthetic general | 0.271 0.042 DBMET02308 | ||
| 0.249 | 0.02 | 0.249 | Acetylcholine antagonist | 0.189 0.034 DBMET02308 | ||
| 0.302 | 0.086 | 0.36 | Antithrombotic | 0.36 0.061 DBMET02308 | DBMET02308 | |
| 0.228 | 0.032 | 0.228 | Acetylcholine M1 receptor antagonist | 0.199 0.043 DBMET02308 | ||
| 0.258 | 0.068 | 0.258 | Antiamyloidogenic | 0.156 0.14 DBMET02308 | ||
| 0.262 | 0.083 | 0.262 | Ca(v)3.3 blocker | 0.242 0.113 DBMET02308 | ||
| 0.335 | 0.159 | 0.335 | Caspase 9 stimulant | 0.282 0.214 DBMET02308 | ||
| 0.244 | 0.078 | 0.376 | Superoxide dismutase inhibitor | 0.376 0.031 DBMET02308 | DBMET02308 | |
| 0.19 | 0.027 | 0.19 | Acetylcholine muscarinic antagonist | 0.156 0.04 DBMET02308 | ||
| 0.161 | 0.014 | 0.161 | Alpha adrenoreceptor agonist | 0.094 0.03 DBMET02308 | ||
| 0.169 | 0.027 | 0.469 | GABA C receptor agonist | 0.469 0.004 DBMET02308 | DBMET02308 | |
| 0.149 | 0.008 | 0.149 | Nicotinic alpha4beta2 receptor antagonist | 0.142 0.01 DBMET02308 | ||
| 0.225 | 0.086 | 0.225 | Vasodilator | |||
| 0.173 | 0.036 | 0.173 | Neuropeptide Y1 antagonist | 0.149 0.066 DBMET02308 | ||
| 0.143 | 0.012 | 0.143 | Acetylcholine M4 receptor antagonist | 0.092 0.035 DBMET02308 | ||
| 0.146 | 0.019 | 0.146 | Acetylcholine release stimulant | 0.11 0.066 DBMET02308 | ||
| 0.186 | 0.059 | 0.186 | Anticoagulant | 0.176 0.063 DBMET02308 | ||
| 0.295 | 0.171 | 0.358 | 5 Hydroxytryptamine release inhibitor | 0.358 0.109 DBMET02308 | DBMET02308 | |
| 0.138 | 0.014 | 0.138 | Neuronal nicotinic receptor antagonist | 0.099 0.025 DBMET02308 | ||
| 0.174 | 0.056 | 0.198 | Neurotensin receptor agonist | 0.198 0.035 DBMET02308 | DBMET02308 | |
| 0.175 | 0.065 | 0.238 | Thrombolytic | 0.238 0.037 DBMET02308 | DBMET02308 | |
| 0.129 | 0.021 | 0.15 | Adrenaline agonist | 0.15 0.014 DBMET02308 | DBMET02308 | |
| 0.221 | 0.117 | 0.258 | Gastrin inhibitor | 0.258 0.07 DBMET02308 | DBMET02308 | |
| 0.156 | 0.054 | 0.156 | Calcium channel blocker | |||
| 0.134 | 0.032 | 0.134 | Sphingomyelinase inhibitor | 0.116 0.044 DBMET02308 | ||
| 0.159 | 0.062 | 0.159 | Protein kinase stimulant | 0.148 0.069 DBMET02308 | ||
| 0.103 | 0.007 | 0.103 | Nicotinic alpha3beta2 receptor antagonist | 0.093 0.009 DBMET02308 | ||
| 0.145 | 0.051 | 0.145 | Nav1.3 sodium channel blocker | 0.141 0.054 DBMET02308 | ||
| 0.095 | 0.007 | 0.165 | Alpha-mannosidase inhibitor | 0.165 0.004 DBMET02308 | DBMET02308 | |
| 0.123 | 0.041 | 0.123 | Toll-Like receptor 4 antagonist | |||
| 0.148 | 0.066 | 0.178 | Adenylate cyclase stimulant | 0.178 0.027 DBMET02308 | DBMET02308 | |
| 0.106 | 0.025 | 0.106 | Dopamine agonist | 0.065 0.048 DBMET02308 | ||
| 0.145 | 0.064 | 0.156 | Neurotrophic factor | 0.156 0.054 DBMET02308 | DBMET02308 | |
| 0.179 | 0.099 | 0.179 | Anticonvulsant | |||
| 0.115 | 0.038 | 0.115 | Calcium antagonist | |||
| 0.078 | 0.009 | 0.151 | Mannosidase inhibitor | 0.151 0.004 DBMET02308 | DBMET02308 | |
| 0.1 | 0.033 | 0.103 | Cathepsin G inhibitor | 0.103 0.032 DBMET02308 | DBMET02308 | |
| 0.117 | 0.053 | 0.144 | Expectorant | 0.144 0.038 DBMET02308 | DBMET02308 | |
| 0.115 | 0.052 | 0.135 | Nav1.1 sodium channel blocker | 0.135 0.04 DBMET02308 | DBMET02308 | |
| 0.108 | 0.047 | 0.151 | Electrolyte absorption antagonist | 0.151 0.019 DBMET02308 | DBMET02308 | |
| 0.065 | 0.005 | 0.07 | Phenylethanolamine N methyltransferase inhibitor | 0.07 0.005 DBMET02308 | DBMET02308 | |
| 0.218 | 0.16 | 0.325 | Interleukin 2 agonist | 0.325 0.058 DBMET02308 | DBMET02308 | |
| 0.081 | 0.023 | 0.116 | Glutamate (mGluR6) antagonist | 0.116 0.006 DBMET02308 | DBMET02308 | |
| 0.073 | 0.015 | 0.073 | Nicotinic receptor alpha4 subunit antagonist | 0.069 0.017 DBMET02308 | ||
| 0.101 | 0.044 | 0.101 | Acetylcholine M3 receptor agonist | 0.076 0.064 DBMET02308 | ||
| 0.08 | 0.026 | 0.08 | Acetylcholine M3 receptor antagonist | 0.073 0.03 DBMET02308 | ||
| 0.184 | 0.131 | 0.234 | Immunostimulant | 0.234 0.103 DBMET02308 | DBMET02308 | |
| 0.172 | 0.12 | 0.172 | Cyclic AMP phosphodiesterase inhibitor | |||
| 0.073 | 0.021 | 0.075 | Heme oxygenase stimulant | 0.075 0.019 DBMET02308 | DBMET02308 | |
| 0.125 | 0.073 | 0.125 | Toll-Like receptor 2 antagonist | 0.123 0.075 DBMET02308 | ||
| 0.094 | 0.044 | 0.094 | Granulocyte macrophage colony stimulating factor agonist | |||
| 0.114 | 0.064 | 0.114 | Calcium channel (voltage-sensitive) blocker | |||
| 0.208 | 0.158 | 0.268 | Cholesterol antagonist | 0.268 0.113 DBMET02308 | DBMET02308 | |
| 0.067 | 0.017 | 0.07 | Prolyl endopeptidase inhibitor | 0.07 0.015 DBMET02308 | DBMET02308 | |
| 0.088 | 0.04 | 0.092 | CC chemokine 5 receptor agonist | 0.092 0.033 DBMET02308 | DBMET02308 | |
| 0.053 | 0.007 | 0.074 | Glutamate (mGluR8) antagonist | 0.074 0.004 DBMET02308 | DBMET02308 | |
| 0.103 | 0.058 | 0.128 | GABA C receptor rho-1 antagonist | 0.128 0.033 DBMET02308 | DBMET02308 | |
| 0.109 | 0.066 | 0.13 | Mucolytic | 0.13 0.046 DBMET02308 | DBMET02308 | |
| 0.12 | 0.078 | 0.308 | Alpha-N-acetylglucosaminidase inhibitor | 0.308 0.015 DBMET02308 | DBMET02308 | |
| 0.099 | 0.057 | 0.154 | Prolactin inhibitor | 0.154 0.02 DBMET02308 | DBMET02308 | |
| 0.18 | 0.139 | 0.277 | Interleukin agonist | 0.277 0.06 DBMET02308 | DBMET02308 | |
| 0.136 | 0.095 | 0.136 | GABA C receptor rho-2 antagonist | |||
| 0.132 | 0.095 | 0.182 | Sphingosine 1-phosphate receptor 5 antagonist | 0.182 0.022 DBMET02308 | DBMET02308 | |
| 0.045 | 0.009 | 0.068 | Tryptophan 5 hydroxylase inhibitor | 0.068 0.003 DBMET02308 | DBMET02308 | |
| 0.067 | 0.032 | 0.067 | Cathepsin E inhibitor | 0.065 0.034 DBMET02308 | ||
| 0.077 | 0.043 | 0.077 | Calcium channel L-type blocker | |||
| 0.105 | 0.071 | 0.147 | GABA C receptor antagonist | 0.147 0.032 DBMET02308 | DBMET02308 | |
| 0.061 | 0.028 | 0.062 | Nicotinic receptor alpha7 subunit antagonist | 0.062 0.027 DBMET02308 | DBMET02308 | |
| 0.067 | 0.039 | 0.115 | NMDA receptor agonist | 0.115 0.015 DBMET02308 | DBMET02308 | |
| 0.051 | 0.023 | 0.06 | Dihydroorotase inhibitor | 0.06 0.016 DBMET02308 | DBMET02308 | |
| 0.051 | 0.024 | 0.054 | Nicotinic receptor alpha3 subunit antagonist | 0.054 0.022 DBMET02308 | DBMET02308 | |
| 0.083 | 0.056 | 0.095 | Inducible nitric-oxide synthase inhibitor | 0.095 0.041 DBMET02308 | DBMET02308 | |
| 0.046 | 0.019 | 0.076 | Kainate receptor agonist | 0.076 0.004 DBMET02308 | DBMET02308 | |
| 0.172 | 0.146 | 0.172 | Calpain inhibitor | |||
| 0.168 | 0.143 | 0.168 | 5 Hydroxytryptamine 3E antagonist | 0.166 0.151 DBMET02308 | ||
| 0.141 | 0.117 | 0.141 | Platelet adhesion inhibitor | |||
| 0.047 | 0.025 | 0.098 | Glutamate (mGluR group III) antagonist | 0.098 0.005 DBMET02308 | DBMET02308 | |
| 0.105 | 0.083 | 0.107 | Microtubule formation inhibitor | 0.107 0.079 DBMET02308 | DBMET02308 | |
| 0.132 | 0.11 | 0.143 | Melanin inhibitor | 0.143 0.091 DBMET02308 | DBMET02308 | |
| 0.067 | 0.045 | 0.067 | Dopamine D2 antagonist | |||
| 0.03 | 0.01 | 0.118 | Glutamate (mGluR1) agonist | 0.118 0.003 DBMET02308 | DBMET02308 | |
| 0.033 | 0.014 | 0.033 | Nicotinic alpha4beta2 receptor agonist | 0.027 0.022 DBMET02308 | ||
| 0.131 | 0.112 | 0.144 | Ca2+-transporting ATPase inhibitor | 0.144 0.059 DBMET02308 | DBMET02308 | |
| 0.105 | 0.086 | 0.105 | Calcium channel N-type blocker | |||
| 0.081 | 0.064 | 0.083 | Ca(v)2.2 blocker | 0.083 0.063 DBMET02308 | DBMET02308 | |
| 0.089 | 0.072 | 0.089 | Alpha 2d adrenoreceptor antagonist | |||
| 0.142 | 0.127 | 0.142 | Non-steroidal antiinflammatory agent | |||
| 0.08 | 0.065 | 0.17 | NMDA receptor antagonist | 0.17 0.019 DBMET02308 | DBMET02308 | |
| 0.032 | 0.018 | 0.032 | Nicotinic alpha3beta4 receptor agonist | 0.027 0.026 DBMET02308 | ||
| 0.058 | 0.044 | 0.058 | Ryanodine receptor antagonist | |||
| 0.044 | 0.03 | 0.101 | Glutamate (mGluR4) antagonist | 0.101 0.005 DBMET02308 | DBMET02308 | |
| 0.069 | 0.055 | 0.139 | Aminopeptidase I inhibitor | 0.139 0.014 DBMET02308 | DBMET02308 | |
| 0.178 | 0.165 | 0.205 | Neuropeptide Y2 antagonist | 0.205 0.111 DBMET02308 | DBMET02308 | |
| 0.062 | 0.049 | 0.062 | Protease 3C (Human rhinovirus) inhibitor | |||
| 0.048 | 0.036 | 0.054 | HCV NS3/NS4A protease inhibitor | 0.054 0.027 DBMET02308 | DBMET02308 | |
| 0.056 | 0.044 | 0.056 | Calcium channel T-type blocker | |||
| 0.046 | 0.034 | 0.048 | Melanocortin antagonist | 0.048 0.032 DBMET02308 | DBMET02308 | |
| 0.024 | 0.013 | 0.096 | Glutamate (mGluR1a) agonist | 0.096 0.004 DBMET02308 | DBMET02308 | |
| 0.133 | 0.122 | 0.133 | Tumour necrosis factor antagonist | |||
| 0.137 | 0.126 | 0.137 | ATPase inhibitor | |||
| 0.094 | 0.085 | 0.111 | Cystathionine beta-synthase inhibitor | 0.111 0.065 DBMET02308 | DBMET02308 | |
| 0.066 | 0.057 | 0.066 | Dopamine antagonist | |||
| 0.082 | 0.074 | 0.082 | Antihistaminic | |||
| 0.104 | 0.096 | 0.133 | Transcription factor STAT6 inhibitor | 0.133 0.04 DBMET02308 | DBMET02308 | |
| 0.025 | 0.019 | 0.03 | Melanocortin 5 antagonist | 0.03 0.015 DBMET02308 | DBMET02308 | |
| 0.037 | 0.031 | 0.07 | GABA uptake inhibitor | 0.07 0.007 DBMET02308 | DBMET02308 | |
| 0.021 | 0.014 | 0.021 | Imidazoline I1 receptor antagonist | |||
| 0.072 | 0.066 | 0.072 | Chymotrypsin inhibitor | |||
| 0.016 | 0.011 | 0.016 | Nicotinic alpha4 receptor agonist | |||
| 0.055 | 0.05 | 0.056 | Acetylcholine M5 receptor antagonist | 0.056 0.048 DBMET02308 | DBMET02308 | |
| 0.112 | 0.108 | 0.121 | Vanilloid 1 agonist | 0.121 0.085 DBMET02308 | DBMET02308 | |
| 0.062 | 0.059 | 0.08 | Glutamate (mGluR7) antagonist | 0.08 0.028 DBMET02308 | DBMET02308 | |
| 0.014 | 0.01 | 0.015 | Somatostatin 2 agonist | 0.015 0.01 DBMET02308 | DBMET02308 | |
| 0.018 | 0.014 | 0.018 | Endothelin B receptor antagonist | |||
| 0.044 | 0.04 | 0.044 | Baculoviral IAP repeat-containing protein inhibitor | 0.044 0.041 DBMET02308 | ||
| 0.053 | 0.051 | 0.053 | Acetylcholine M2 receptor antagonist | |||
| 0.089 | 0.087 | 0.091 | Glutamate (mGluR7) agonist | 0.091 0.08 DBMET02308 | DBMET02308 | |
| 0.028 | 0.027 | 0.028 | Epoxide hydrolase 1 inhibitor | |||
| 0.059 | 0.057 | 0.064 | Prolactin release inhibitor | 0.064 0.038 DBMET02308 | DBMET02308 | |
| 0.066 | 0.064 | 0.073 | Glycine receptor agonist | 0.073 0.049 DBMET02308 | DBMET02308 | |
| 0.033 | 0.032 | 0.113 | NMDA receptor subunit 3A antagonist | 0.113 0.007 DBMET02308 | DBMET02308 | |
| 0.031 | 0.03 | 0.031 | ADAM10 endopeptidase inhibitor | 0.031 0.028 DBMET02308 | ||
| 0.073 | 0.072 | 0.089 | MAP kinase kinase 7 inhibitor | 0.089 0.026 DBMET02308 | DBMET02308 | |
| 0.047 | 0.046 | 0.047 | Histamine agonist | 0.047 0.046 DBMET02308 | ||
| 0.035 | 0.035 | 0.054 | Dopamine D5 agonist | 0.054 0.014 DBMET02308 | DBMET02308 | |
| 0.033 | 0.032 | 0.039 | Nicotinic receptor beta4 subunit antagonist | 0.039 0.023 DBMET02308 | DBMET02308 | |
| 0.029 | 0.029 | 0.039 | Dipeptidyl peptidase II inhibitor | 0.039 0.015 DBMET02308 | DBMET02308 | |
| 0.035 | 0.036 | 0.053 | Membrane dipeptidase inhibitor | 0.053 0.014 DBMET02308 | DBMET02308 | |
| 0.03 | 0.031 | 0.064 | Arginase inhibitor | 0.064 0.009 DBMET02308 | DBMET02308 | |
| 0.169 | 0.17 | 0.213 | DNA synthesis inhibitor | 0.213 0.104 DBMET02308 | DBMET02308 | |
| 0.053 | 0.055 | 0.078 | Sphingosine kinase inhibitor | 0.078 0.018 DBMET02308 | DBMET02308 | |
| 0.019 | 0.022 | 0.021 | Aminopeptidase P inhibitor | 0.021 0.019 DBMET02308 | DBMET02308 | |
| 0.038 | 0.041 | 0.048 | GABA B receptor antagonist | 0.048 0.022 DBMET02308 | DBMET02308 | |
| 0.029 | 0.033 | 0.043 | Glutamate (mGluR3) agonist | 0.043 0.008 DBMET02308 | DBMET02308 | |
| 0.091 | 0.097 | 0.1 | DOPA decarboxylase inhibitor | 0.1 0.076 DBMET02308 | DBMET02308 | |
| 0.033 | 0.041 | 0.036 | Glucose-6-phosphate dehydrogenase inhibitor | 0.036 0.031 DBMET02308 | DBMET02308 | |
| 0.07 | 0.08 | 0.095 | Histamine N-methyltransferase inhibitor | 0.095 0.051 DBMET02308 | DBMET02308 | |
| 0.02 | 0.03 | 0.052 | Lysine carboxypeptidase inhibitor | 0.052 0.007 DBMET02308 | DBMET02308 | |
| 0.015 | 0.025 | 0.02 | Tryptophan hydroxylase 1 inhibitor | 0.02 0.007 DBMET02308 | DBMET02308 | |
| 0.015 | 0.025 | 0.026 | Integrin alphaVbeta1 antagonist | 0.026 0.007 DBMET02308 | DBMET02308 | |
| 0.121 | 0.131 | 0.125 | Interferon gamma antagonist | 0.125 0.122 DBMET02308 | DBMET02308 | |
| 0.023 | 0.034 | 0.029 | Endothelial nitric-oxide synthase inhibitor | 0.029 0.024 DBMET02308 | DBMET02308 | |
| 0.005 | 0.017 | 0.011 | Integrin alphaVbeta5 antagonist | 0.011 0.006 DBMET02308 | DBMET02308 | |
| 0.081 | 0.095 | 0.093 | Nitric-oxide synthase inhibitor | 0.093 0.073 DBMET02308 | DBMET02308 | |
| 0.045 | 0.059 | 0.058 | CXC chemokine 4 receptor antagonist | 0.058 0.044 DBMET02308 | DBMET02308 | |
| 0.029 | 0.044 | 0.066 | Glutamate (mGluR3) antagonist | 0.066 0.007 DBMET02308 | DBMET02308 | |
| 0.033 | 0.048 | 0.118 | NMDA receptor subunit 3B antagonist | 0.118 0.009 DBMET02308 | DBMET02308 | |
| 0.041 | 0.057 | 0.055 | Plasminogen activator inhibitor | 0.055 0.043 DBMET02308 | DBMET02308 | |
| 0.023 | 0.041 | 0.039 | Leukotriene A4 hydrolase inhibitor | 0.039 0.026 DBMET02308 | DBMET02308 | |
| 0.052 | 0.07 | 0.137 | Leukotriene synthesis inhibitor | 0.137 0.012 DBMET02308 | DBMET02308 | |
| 0.029 | 0.047 | 0.05 | Integrin alpha2 antagonist | 0.05 0.011 DBMET02308 | DBMET02308 | |
| 0.033 | 0.052 | 0.051 | Sphingosine kinase 1 inhibitor | 0.051 0.015 DBMET02308 | DBMET02308 | |
| 0.094 | 0.114 | 0.118 | Cyclooxygenase 3 inhibitor | 0.118 0.08 DBMET02308 | DBMET02308 | |
| 0.021 | 0.043 | 0.026 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.026 0.021 DBMET02308 | DBMET02308 | |
| 0.044 | 0.067 | 0.055 | Angiotensin-converting enzyme inhibitor | 0.055 0.038 DBMET02308 | DBMET02308 | |
| 0.024 | 0.049 | 0.031 | Carnitine palmitoyltransferase 1 inhibitor | 0.031 0.029 DBMET02308 | DBMET02308 | |
| 0.006 | 0.031 | 0.021 | Integrin alpha4beta1 antagonist | 0.021 0.009 DBMET02308 | DBMET02308 | |
| 0.107 | 0.133 | 0.143 | Sphingosine 1-phosphate receptor 2 antagonist | 0.143 0.05 DBMET02308 | DBMET02308 | |
| 0.044 | 0.07 | 0.064 | Androgen agonist | 0.064 0.036 DBMET02308 | DBMET02308 | |
| 0.068 | 0.096 | 0.168 | Aminopeptidase B inhibitor | 0.168 0.031 DBMET02308 | DBMET02308 | |
| 0.253 | 0.283 | 0.288 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.288 0.23 DBMET02308 | DBMET02308 | |
| 0.012 | 0.044 | 0.02 | Integrin beta5 antagonist | 0.02 0.015 DBMET02308 | DBMET02308 | |
| 0.01 | 0.042 | 0.085 | VLA-4 antagonist | 0.085 0.007 DBMET02308 | DBMET02308 | |
| 0.025 | 0.058 | 0.039 | Oxytocin agonist | 0.039 0.033 DBMET02308 | DBMET02308 | |
| 0.086 | 0.119 | 0.1 | Caspase 3 inhibitor | 0.1 0.091 DBMET02308 | DBMET02308 | |
| 0.049 | 0.083 | 0.061 | Caspase 9 inhibitor | 0.061 0.046 DBMET02308 | DBMET02308 | |
| 0.003 | 0.038 | 0.007 | Integrin alpha5beta6 antagonist | 0.007 0.004 DBMET02308 | DBMET02308 | |
| 0.041 | 0.076 | 0.065 | Carbonic anhydrase stimulant | 0.065 0.036 DBMET02308 | DBMET02308 | |
| 0.024 | 0.06 | 0.035 | Carboxypeptidase B inhibitor | 0.035 0.02 DBMET02308 | DBMET02308 | |
| 0.127 | 0.164 | 0.151 | Phospholipase C inhibitor | 0.151 0.103 DBMET02308 | DBMET02308 | |
| 0.089 | 0.127 | 0.116 | Interleukin 8 antagonist | 0.116 0.067 DBMET02308 | DBMET02308 | |
| 0.027 | 0.066 | 0.071 | NMDA 2A receptor antagonist | 0.071 0.024 DBMET02308 | DBMET02308 | |
| 0.056 | 0.095 | 0.07 | GABA aminotransferase inhibitor | 0.07 0.062 DBMET02308 | DBMET02308 | |
| 0.007 | 0.049 | 0.013 | Integrin alphaVbeta6 antagonist | 0.013 0.012 DBMET02308 | DBMET02308 | |
| 0.018 | 0.062 | 0.116 | Integrin antagonist | 0.116 0.014 DBMET02308 | DBMET02308 | |
| 0.019 | 0.063 | 0.042 | Free fatty acid receptor 1 antagonist | 0.042 0.014 DBMET02308 | DBMET02308 | |
| 0.016 | 0.061 | 0.072 | Kainate receptor 2 antagonist | 0.072 0.008 DBMET02308 | DBMET02308 | |
| 0.017 | 0.064 | 0.029 | Integrin alpha2beta1 antagonist | 0.029 0.014 DBMET02308 | DBMET02308 | |
| 0.036 | 0.084 | 0.057 | NMDA receptor glycine site agonist | 0.057 0.049 DBMET02308 | DBMET02308 | |
| 0.008 | 0.057 | 0.053 | Integrin alpha4 antagonist | 0.053 0.011 DBMET02308 | DBMET02308 | |
| 0.035 | 0.083 | 0.066 | Aconitate hydratase inhibitor | 0.066 0.021 DBMET02308 | DBMET02308 | |
| 0.037 | 0.086 | 0.084 | NMDA 2C receptor antagonist | 0.084 0.023 DBMET02308 | DBMET02308 | |
| 0.124 | 0.178 | 0.163 | Platelet antagonist | 0.163 0.132 DBMET02308 | DBMET02308 | |
| 0.037 | 0.092 | 0.058 | Sphingosine 1-phosphate receptor 3 antagonist | 0.058 0.041 DBMET02308 | DBMET02308 | |
| 0.122 | 0.177 | 0.183 | Succinate dehydrogenase inhibitor | 0.183 0.065 DBMET02308 | DBMET02308 | |
| 0.018 | 0.073 | 0.07 | Kainate receptor antagonist | 0.07 0.012 DBMET02308 | DBMET02308 | |
| 0.065 | 0.12 | 0.135 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.135 0.032 DBMET02308 | DBMET02308 | |
| 0.171 | 0.229 | 0.193 | Apoptosis antagonist | 0.193 0.189 DBMET02308 | DBMET02308 | |
| 0.099 | 0.16 | 0.143 | Angiogenesis stimulant | 0.143 0.127 DBMET02308 | DBMET02308 | |
| 0.023 | 0.083 | 0.036 | Integrin alpha5beta1 antagonist | 0.036 0.035 DBMET02308 | DBMET02308 | |
| 0.025 | 0.086 | 0.06 | AMPA 4 receptor antagonist | 0.06 0.01 DBMET02308 | DBMET02308 | |
| 0.035 | 0.1 | 0.102 | Phosphofructokinase-1 inhibitor | 0.102 0.031 DBMET02308 | DBMET02308 | |
| 0.005 | 0.069 | 0.034 | Kainate receptor 1 antagonist | 0.034 0.009 DBMET02308 | DBMET02308 | |
| 0.072 | 0.137 | 0.15 | Amylase inhibitor | 0.15 0.064 DBMET02308 | DBMET02308 | |
| 0.083 | 0.149 | 0.109 | Cathepsin H inhibitor | 0.109 0.09 DBMET02308 | DBMET02308 | |
| 0.029 | 0.097 | 0.083 | Argininosuccinate synthase inhibitor | 0.083 0.024 DBMET02308 | DBMET02308 | |
| 0.024 | 0.096 | 0.037 | Glutamate (mGluR8) agonist | 0.037 0.029 DBMET02308 | DBMET02308 | |
| 0.01 | 0.082 | 0.042 | AMPA 3 receptor antagonist | 0.042 0.012 DBMET02308 | DBMET02308 | |
| 0.057 | 0.132 | 0.122 | HIV-1 integrase (Overall Integration) inhibitor | 0.122 0.038 DBMET02308 | DBMET02308 | |
| 0.021 | 0.102 | 0.042 | Geranyltranstransferase inhibitor | 0.042 0.034 DBMET02308 | DBMET02308 | |
| 0.054 | 0.136 | 0.073 | Vanilloid 4 agonist | 0.073 0.056 DBMET02308 | DBMET02308 | |
| 0.058 | 0.143 | 0.12 | Triose-phosphate isomerase inhibitor | 0.12 0.032 DBMET02308 | DBMET02308 | |
| 0.085 | 0.179 | 0.136 | Diuretic | 0.136 0.089 DBMET02308 | DBMET02308 | |
| 0.036 | 0.137 | 0.091 | Glutamate decarboxylase inhibitor | 0.091 0.035 DBMET02308 | DBMET02308 | |
| 0.009 | 0.11 | 0.026 | AMPA 2 receptor antagonist | 0.026 0.024 DBMET02308 | DBMET02308 | |
| 0.026 | 0.133 | 0.037 | Integrin alpha1beta1 antagonist | 0.037 0.031 DBMET02308 | DBMET02308 | |
| 0.052 | 0.161 | 0.078 | GABA B receptor agonist | 0.078 0.047 DBMET02308 | DBMET02308 | |
| 0.025 | 0.141 | 0.066 | Carbamoyl phosphate synthetase inhibitor | 0.066 0.038 DBMET02308 | DBMET02308 | |
| 0.082 | 0.204 | 0.125 | Arachidonic acid antagonist | 0.125 0.119 DBMET02308 | DBMET02308 | |
| 0.061 | 0.184 | 0.092 | Nav1.4 sodium channel blocker | 0.092 0.089 DBMET02308 | DBMET02308 | |
| 0.038 | 0.175 | 0.079 | Glutamate dehydrogenase inhibitor | 0.079 0.046 DBMET02308 | DBMET02308 | |
| 0.032 | 0.17 | 0.067 | Phospholipase D inhibitor | 0.067 0.06 DBMET02308 | DBMET02308 | |
| 0.148 | 0.291 | 0.267 | Histamine release inhibitor | 0.267 0.143 DBMET02308 | DBMET02308 | |
| 0.057 | 0.207 | 0.084 | Hematopoietic | 0.084 0.061 DBMET02308 | DBMET02308 | |
| 0.061 | 0.212 | 0.093 | Adenylate kinase inhibitor | 0.093 0.08 DBMET02308 | DBMET02308 | |
| 0.073 | 0.225 | 0.134 | Cell wall synthesis inhibitor | 0.134 0.082 DBMET02308 | DBMET02308 | |
| 0.025 | 0.18 | 0.083 | Phenylalanine 4-hydroxylase inhibitor | 0.083 0.035 DBMET02308 | DBMET02308 | |
| 0.096 | 0.252 | 0.146 | Neurotrophic factor enhancer | 0.146 0.143 DBMET02308 | DBMET02308 | |
| 0.046 | 0.204 | 0.143 | Ferrochelatase inhibitor | 0.143 0.041 DBMET02308 | DBMET02308 | |
| 0.02 | 0.18 | 0.057 | Biliverdin reductase inhibitor | 0.057 0.044 DBMET02308 | DBMET02308 | |
| 0.049 | 0.21 | 0.079 | NADH dehydrogenase inhibitor | 0.079 0.078 DBMET02308 | DBMET02308 | |
| 0.083 | 0.247 | 0.173 | Aldehyde oxidase inhibitor | 0.173 0.121 DBMET02308 | DBMET02308 | |
| 0.021 | 0.226 | 0.076 | Porphobilinogen synthase inhibitor | 0.076 0.05 DBMET02308 | DBMET02308 | |
| 0.033 | 0.268 | 0.084 | Creatine kinase inhibitor | 0.084 0.081 DBMET02308 | DBMET02308 | |
| 0.068 | 0.312 | 0.135 | Insulin secretagoues | 0.135 0.09 DBMET02308 | DBMET02308 | |
| 0.104 | 0.376 | 0.232 | Sodium/bile acid cotransporter inhibitor | 0.232 0.148 DBMET02308 | DBMET02308 | |
| 0.076 | 0.459 | 0.383 | Toll-Like receptor agonist | 0.383 0.067 DBMET02308 | DBMET02308 | |
| 0.077 | 0.46 | 0.382 | Toll-Like receptor 7 agonist | 0.382 0.067 DBMET02308 | DBMET02308 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |